Mechanism of action
Guanfacine is a selective α2A-adrenergic receptor agonist with 15-20 times greater selectivity for α2A receptors compared to clonidine. Its mechanism differs depending on the receptor location.
Central mechanism (ADHD)
Guanfacine acts primarily on postsynaptic α2A-adrenergic receptors in the prefrontal cortex (PFC). By stimulating these receptors, it strengthens prefrontal cortical regulation of attention and behavior. The drug enhances delay-related firing of PFC neurons, improving working memory and executive function. This occurs through closure of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels on dendritic spines, which reduces neuronal noise and enhances signal strength.
Guanfacine improves the efficacy of PFC networks involved in:
- Working memory - maintains information in mind
- Response inhibition - reduces impulsivity
- Attention regulation - filters distractions
- Behavioral control - decreases hyperactivity
Peripheral mechanism (hypertension)
In the cardiovascular system, guanfacine stimulates presynaptic α2A receptors in the brainstem (locus coeruleus and medulla oblongata). This activation reduces sympathetic outflow from the central nervous system, leading to decreased peripheral vascular resistance, heart rate, and blood pressure. Unlike direct vasodilators, guanfacine does not cause reflex tachycardia because it reduces central sympathetic tone.
The selectivity for α2A receptors (rather than α2B or α2C subtypes) contributes to reduced sedation compared to clonidine, though somnolence remains a common side effect, especially during initiation.
- Guanfacine is a selective α2A-adrenergic agonist more selective than clonidine, reducing sedation.
- Mechanism for ADHD: stimulates postsynaptic α2A receptors in prefrontal cortex, improving working memory and inhibitory control.
- Primary use is ADHD in children/adolescents; can be combined with stimulants for complementary effects.
- Key adverse effects: somnolence (most common), hypotension, bradycardia, and dry mouth.
- Abrupt discontinuation causes rebound hypertension—always taper gradually over several days.
- Metabolized by CYP3A4: strong inhibitors increase levels (reduce dose), inducers decrease levels (may need dose increase).
- Extended-release formulation is preferred for ADHD due to once-daily dosing and reduced peak-related sedation.
- Not a controlled substance, making it easier to prescribe than stimulants with no abuse potential.
Indications
FDA-approved indications
ADHD (primary indication) - Guanfacine extended-release is approved as monotherapy or adjunctive therapy to stimulants for ADHD in children aged 6-17 years and adults. It is particularly useful for patients who cannot tolerate stimulants, have contraindications to stimulants (cardiac concerns, substance abuse history), or experience residual symptoms despite stimulant therapy. Guanfacine addresses the prefrontal cortex dysfunction underlying ADHD and is especially effective for hyperactivity and impulsivity.
Hypertension - Immediate-release guanfacine is approved for hypertension, though it is rarely used as a first-line agent. It may be considered in patients with comorbid ADHD or when other antihypertensives are contraindicated.
Off-label uses
- Tourette syndrome and tic disorders - reduces tic frequency and severity
- Post-traumatic stress disorder (PTSD) - particularly for hyperarousal and nightmares
- Autism spectrum disorder - for hyperactivity and aggression
- Opioid withdrawal - reduces sympathetic hyperactivity symptoms
- Insomnia associated with ADHD
The extended-release formulation is preferred for ADHD due to once-daily dosing and reduced peak-related side effects.
Pharmacokinetics
Absorption - Guanfacine is well absorbed orally with approximately 80% bioavailability. Peak plasma concentrations occur 1-4 hours after immediate-release and 5-7 hours after extended-release administration. Food (especially high-fat meals) increases exposure to extended-release guanfacine by up to 75%, so it should be taken consistently with or without food.
Distribution - Volume of distribution is 6.3 L/kg. Guanfacine is 70% protein-bound, primarily to albumin. It crosses the blood-brain barrier readily to exert central effects.
Metabolism - Guanfacine undergoes hepatic metabolism primarily via CYP3A4 (and to a lesser extent CYP3A5). Major metabolites include 3-hydroxy-guanfacine and inactive oxidative metabolites. Importantly, guanfacine exhibits linear pharmacokinetics (dose-proportional exposure).
Excretion - Elimination half-life is approximately 17 hours in adults and 14 hours in children, allowing once-daily dosing. About 40-50% is excreted unchanged in urine, with the remainder as metabolites. Renal impairment reduces clearance significantly.
Special populations
- Hepatic impairment - clearance decreased; dose reduction warranted
- Renal impairment - dose adjustment required (reduce by 50% if CrCl <30 mL/min)
- Pediatric patients - faster clearance necessitating weight-based dosing
- Elderly - reduced clearance may require lower doses
CYP3A4 inducers (rifampin, phenytoin) significantly reduce guanfacine levels, while CYP3A4 inhibitors (ketoconazole, clarithromycin) increase levels substantially.
Adverse effects
Common adverse effects (>10%)
- Somnolence and sedation (35-50%) - most common, usually improves with continued use; dose-dependent
- Fatigue - often accompanies somnolence
- Hypotension (5-15%) - orthostatic hypotension possible, especially with rapid titration
- Dry mouth (15-25%) - anticholinergic-like effect
- Headache
- Abdominal pain and nausea
- Dizziness
- Bradycardia - heart rate reduction of 5-10 bpm typical
Serious adverse effects
Cardiovascular effects - Significant hypotension and bradycardia can occur, particularly in patients with baseline low blood pressure or concurrent use of other antihypertensives. Syncope has been reported. Pre-treatment blood pressure and heart rate should be assessed, with periodic monitoring during treatment.
Rebound hypertension - Abrupt discontinuation (especially in patients on immediate-release formulation for hypertension) can cause rebound hypertension with blood pressure exceeding baseline values. Taper gradually over 2-7 days when discontinuing.
Cardiac conduction abnormalities - QT prolongation, AV block (rare), and sinus node dysfunction have been reported, particularly with overdose.
Sedation-related impairment - Can impair cognitive and motor performance, increasing risk of accidents. Patients should be cautioned about driving and operating machinery, especially during initiation.
Allergic reactions - Rare cases of angioedema and hypersensitivity reactions
Psychiatric effects
Depression, mood changes, and hallucinations have been reported rarely. There is a slight increased risk of suicidal ideation in pediatric patients, though causality is unclear.
Other considerations
Weight changes - Weight gain may occur, particularly in pediatric patients; monitor growth parameters. Constipation - less common than with other α2 agonists but can occur.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to guanfacine or any formulation component
Warnings and precautions
Cardiovascular disease - Use with extreme caution in patients with heart block, bradycardia, severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal/hepatic failure. Baseline ECG may be warranted in at-risk patients. Monitor heart rate and blood pressure before initiation and during dose titration.
Abrupt discontinuation - Never stop guanfacine abruptly, especially in hypertensive patients. Rebound hypertension, nervousness, anxiety, and tremor can occur. Taper by no more than 1 mg every 3-7 days. If doses are missed for more than 2-3 days, consider retitration from a lower dose.
Sedation and impaired alertness - Somnolence is prominent, especially during the first 2-4 weeks. Activities requiring alertness (driving, operating machinery) should be limited until individual response is known. Avoid concurrent CNS depressants.
Hypotension and syncope - Most likely during initial titration or with dose increases. Measure blood pressure in sitting and standing positions. Instruct patients to rise slowly from lying/sitting positions. Increased risk with dehydration or concurrent antihypertensives.
Pregnancy and lactation - Pregnancy category B. Limited human data, but animal studies show no teratogenicity. Use only if benefit outweighs risk. Guanfacine is excreted in breast milk; discontinue nursing or discontinue drug depending on maternal need.
Renal and hepatic impairment - Dose reduction required. Enhanced drug accumulation and prolonged half-life increase adverse effect risk.
Psychiatric history - Monitor for worsening depression or emergence of suicidal thoughts, particularly in adolescents.
Pediatric considerations - Growth parameters (height, weight) should be monitored. Sedation may impact school performance initially.
Drug interactions
Major interactions (CYP3A4 system)
CYP3A4 inhibitors - Ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice significantly increase guanfacine levels (up to 2-3-fold). Consider dose reduction (often by 50%) when strong inhibitors are started. Monitor for hypotension, bradycardia, and excessive sedation.
CYP3A4 inducers - Rifampin, carbamazepine, phenytoin, St. John's wort markedly decrease guanfacine levels, potentially leading to loss of efficacy or rebound hypertension. May need dose increase (consider doubling dose) if strong inducers are necessary; monitor for loss of therapeutic effect.
Cardiovascular interactions
Antihypertensives - Additive hypotensive effects with other antihypertensives (beta-blockers, calcium channel blockers, ACE inhibitors, diuretics). Combination with beta-blockers or non-dihydropyridine calcium channel blockers increases risk of bradycardia and AV block. Monitor blood pressure and heart rate closely.
Digoxin - Potential for additive bradycardia; monitor heart rate and consider ECG.
QT-prolonging drugs - Additive QT prolongation with macrolide antibiotics, antipsychotics, and Class IA/III antiarrhythmics (theoretical risk, poorly documented).
CNS depressants
Alcohol, benzodiazepines, opioids, barbiturates, sedating antihistamines - Additive CNS depression leading to excessive sedation, respiratory depression, and cognitive impairment. Avoid combination or use with extreme caution.
Other sedating psychotropics - Antipsychotics, tricyclic antidepressants, and sedating antidepressants potentiate sedation.
Stimulants (in ADHD treatment)
Guanfacine is often combined with stimulants (methylphenidate, amphetamines) without significant pharmacokinetic interaction. The combination can provide complementary benefits—stimulants improve attention/focus while guanfacine reduces hyperactivity/impulsivity. Monitor for cardiovascular effects as both can affect heart rate and blood pressure (though often in opposite directions).
Valproic acid
Guanfacine may increase valproic acid levels; monitor valproic acid concentrations and watch for signs of valproate toxicity (sedation, tremor, gastrointestinal effects). Dose adjustment of valproic acid may be necessary.
NSAIDs
May reduce antihypertensive efficacy by promoting sodium retention and inhibiting prostaglandin-mediated vasodilation.
Clinical pearls
Start low, go slow - Begin with the lowest dose and titrate slowly (no faster than weekly) to minimize sedation and cardiovascular effects. Many adverse effects are transient and resolve with continued use.
Extended-release is preferred for ADHD - Once-daily dosing improves adherence, and the smoother plasma profile reduces peak-related sedation compared to immediate-release formulation.
Combination therapy in ADHD - Guanfacine is often added to stimulants when response is partial or when targeting specific residual symptoms (emotional dysregulation, impulsivity, sleep problems). It can also be used as monotherapy when stimulants are contraindicated or poorly tolerated.
Cardiovascular monitoring - Check pulse and blood pressure before starting, after dose increases, and periodically during maintenance. Sitting and standing measurements help identify orthostatic hypotension. Heart rate reductions of 10-15 bpm are common and usually well-tolerated.
Timing matters - Taking guanfacine at bedtime can leverage the sedative effect as a benefit for sleep initiation, while minimizing daytime impairment.
Food effects with extended-release - Extended-release guanfacine should not be taken with high-fat meals, as this significantly increases drug exposure (up to 75% increase in peak concentration). Instruct patients to avoid high-fat meals when taking the medication.
Don't crush or split extended-release tablets - This destroys the controlled-release properties and causes dose dumping with increased side effects and reduced duration of action.
Rebound prevention - If switching from immediate-release to extended-release, overlap formulations briefly. If discontinuing, taper gradually. Missed doses require clinical judgment—if 2+ days are missed, consider restarting at a lower dose.
Less sedating than clonidine - Greater α2A selectivity translates to reduced sedation compared to clonidine, making guanfacine often better tolerated for ADHD, though individual response varies.
Not a controlled substance - Unlike stimulants, guanfacine has no abuse potential and is not a scheduled drug, making it easier to prescribe and refill.
Tic disorders - Effective for both ADHD and comorbid tics, addressing both conditions simultaneously (unlike stimulants, which may worsen tics).
Monitor in elderly - Increased fall risk due to orthostatic hypotension; start with very low doses and monitor closely.
Practice questions
1. A 9-year-old boy with ADHD is started on guanfacine extended-release for persistent impulsivity and hyperactivity despite adequate trials of methylphenidate. After 2 weeks at therapeutic dose, his teacher reports improved behavioral control, but his parents note he falls asleep in the car after school and seems 'sluggish' in the evenings. Vital signs show BP 95/60 mmHg (baseline 108/68) and HR 62 bpm (baseline 78). What is the most appropriate next step?
2. A 14-year-old girl has been taking guanfacine extended-release 4 mg daily for ADHD with good symptom control. She is prescribed clarithromycin for community-acquired pneumonia. Three days later, she presents to the emergency department with dizziness, near-syncope, and extreme fatigue. Vital signs: BP 82/50 mmHg lying, 70/45 mmHg standing; HR 48 bpm. What is the most likely explanation for her presentation?
3. A 45-year-old man with hypertension has been taking immediate-release guanfacine 2 mg twice daily for 6 months with good blood pressure control. He runs out of medication and does not refill his prescription for 4 days. He presents with severe headache, blood pressure 190/110 mmHg (baseline on treatment 130/80), tremor, anxiety, and diaphoresis. What is the mechanism of his current presentation?
Frequently asked questions
How does guanfacine work for ADHD?
Guanfacine works by stimulating postsynaptic α2A-adrenergic receptors in the prefrontal cortex, the brain region responsible for executive functions. This activation strengthens prefrontal cortical networks involved in working memory, attention regulation, and impulse control. Unlike stimulants that increase dopamine and norepinephrine release, guanfacine directly enhances the efficiency of prefrontal cortex neurons by reducing neuronal noise and improving signal-to-noise ratio through closure of HCN channels on dendritic spines.
What are the side effects of guanfacine?
The most common side effects of guanfacine are somnolence and sedation, affecting 35-50% of patients, especially during the first few weeks. Other frequent side effects include fatigue, dry mouth, hypotension, headache, dizziness, abdominal pain, and bradycardia. Serious but less common effects include significant drops in blood pressure causing syncope, cardiac conduction abnormalities, and rebound hypertension if stopped abruptly. Most side effects improve with continued use and can be minimized by slow dose titration.
Is guanfacine a controlled substance?
No, guanfacine is not a controlled substance and is not scheduled by the DEA. Unlike stimulant medications commonly used for ADHD (such as methylphenidate and amphetamines), guanfacine has no abuse potential or risk of dependence. This makes it easier to prescribe, allows for refills without requiring a new prescription each time, and makes it a valuable alternative for patients with a history of substance abuse or in situations where stimulant diversion is a concern.
Guanfacine vs clonidine — what is the difference?
Both guanfacine and clonidine are α2-adrenergic agonists used for ADHD, but guanfacine is 15-20 times more selective for the α2A receptor subtype compared to clonidine. This greater selectivity results in less sedation and fewer autonomic side effects with guanfacine, though somnolence still occurs. Guanfacine has a longer half-life (17 hours vs 12 hours), allowing once-daily dosing with more stable drug levels. Clonidine may be preferred for immediate management of aggression or severe hyperarousal, while guanfacine is often better tolerated for chronic ADHD management.
Can you stop taking guanfacine suddenly?
No, you should never stop guanfacine abruptly, as this can cause serious rebound effects, especially rebound hypertension where blood pressure rises above baseline levels. Other withdrawal symptoms include nervousness, anxiety, agitation, tremor, and headache. Guanfacine must be tapered gradually over at least 2-7 days, reducing the dose by no more than 1 mg every few days. If doses have been missed for more than 2-3 consecutive days, do not simply resume the previous dose—contact your prescriber, as retitration from a lower dose may be necessary to avoid adverse effects.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C02AC02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.